Wang Jin, Wu Shikui, Wang Mingsheng
Department of Urology, The First Hospital of Xuzhou Mining Group, Xuzhou, 221131, China.
Iran J Public Health. 2024 Mar;53(3):495-507. doi: 10.18502/ijph.v53i3.15131.
Patients with benign prostatic hyperplasia are generally treated holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP). Therefore, it is important to analyze the several surgical procedures used for benign prostatic hyperplasia in terms of their role, effectiveness and safety.
We conducted a meta-analysis by searching databases of PubMed, Google Scholar, and Web of Science. Finally, we selected 10 papers including 2,456 patients treated with of thulium laser and holmium laser in the surgical treatment of benign prostatic hyperplasia. We did the analysis using RevMan 5.0 with the selected studies until 26 October 2023.
ThuLEP resulted in a smaller reduction in haemoglobin (MD: -0.22, 95%CI -0.32 to -0.13, <0.001) and a shorter hospital stay (MD: -0.29, 95%CI -0.38 to -0.20, <0.001). During the postoperative follow-ups, only the IPSS (MD: -0.03; 95%CI -0.11 to -0.06; 0.58) at the six-month showed statistically significant differences.
ThuLEP has greater security and faster growth than HoLEP.
良性前列腺增生患者一般采用钬激光前列腺剜除术（HoLEP）和铥激光前列腺剜除术（ThuLEP）进行治疗。因此，从其作用、有效性和安全性方面分析用于良性前列腺增生的几种手术方法很重要。
我们通过检索PubMed、谷歌学术和科学网数据库进行了一项荟萃分析。最后，我们选择了10篇论文，包括2456例接受铥激光和钬激光手术治疗良性前列腺增生的患者。我们使用RevMan 5.0对所选研究进行分析，直至2023年10月26日。
ThuLEP导致血红蛋白下降幅度较小（MD：-0.22，95%CI -0.32至-0.13，<0.001）且住院时间较短（MD：-0.29，95%CI -0.38至-0.20，<0.001）。在术后随访期间，仅六个月时的国际前列腺症状评分（MD：-0.03；95%CI -0.11至-0.06；0.58）显示出统计学上的显著差异。
ThuLEP比HoLEP具有更高的安全性和更快的恢复速度。
